Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose among the key challenges ...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, e-commerce, Drug Stores and Others) & Region for 2024 to ...

AXS-12 is an investigational highly selective potent norepinephrine reuptake inhibitor and cortical dopamine modulator.

potentially offering new treatments for narcolepsy and neurological disorders. This development could position NLS as a significant player in the biopharmaceutical market, with plans to expand ...

Research and development activities, coupled with a rising demand for effective narcolepsy treatments, are additional factors fueling market expansion. However, challenges such as low per capita ...

(MENAFN- GlobeNewsWire - Nasdaq) Narcolepsy treatment market by Product (Narcolepsy Treatment Drugs and Devices), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, e-commerce ...

A collection of common and new medications is showing good results against the constellation of symptoms that individualize ...

Centessa's pipeline is anchored by two main drug candidates: ORX750 for narcolepsy and SerpinPC for hemophilia B. These innovative treatments are positioned to potentially disrupt their respective ...

ORX750, Centessa's orexin agonist, is poised to make waves in the narcolepsy treatment landscape. The drug is part of a new class of treatments that offer significant clinical benefits over existing ...